Please contact our sales team for your Consulting and Customization queries/concerns at [email protected].
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
Market Analysis and Insights: Global Microbiome Drugs Market
The global Microbiome Drugs market is projected to grow from US$ 305.3 million in 2023 to US$ 1815.7 million by 2029, at a Compound Annual Growth Rate (CAGR) of 34.6% during the forecast period.
North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.
Report Includes
This report presents an overview of global market for Microbiome Drugs market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Microbiome Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Microbiome Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Microbiome Drugs revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Microbiome Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by symptom, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Microbiome Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc.
By Company
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Interxon
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- AOBiome
- Rebiotix
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Osel
Segment by Type
- Oral Dosage Form
- Enteric Capsules
Segment by Symptom
- Gastrointestinal Disorders
- Autoimmune Disorders
- Diabetes
- Cancer
- Others
By Region
- North America
- - United States
- - Canada
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- - Nordic Countries
- - Rest of Europe
- Asia-Pacific
- - China
- - Japan
- - South Korea
- - Southeast Asia
- - India
- - Australia
- - Rest of Asia
- Latin America
- - Mexico
- - Brazil
- - Rest of Latin America
- Middle East, Africa, and Latin America
- - Turkey
- - Saudi Arabia
- - UAE
- - Rest of MEA
Chapter Outline
Chapter 1: Introduces the Report Scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Microbiome Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Microbiome Drugs companiesÂ’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by symptom, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by symptom and by country, revenue for each segment.
Chapter 7: Europe by type, by symptom and by country, revenue for each segment.
Chapter 8: China by type and by symptom revenue for each segment.
Chapter 9: Asia (excluding China) by type, by symptom and By Region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by symptom and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Microbiome Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Oral Dosage Form
1.2.3 Enteric Capsules
1.3 Market by Symptom
1.3.1 Global Microbiome Drugs Market Size Growth Rate by Symptom, 2018 VS 2022 VS 2029
1.3.2 Gastrointestinal Disorders
1.3.3 Autoimmune Disorders
1.3.4 Diabetes
1.3.5 Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Microbiome Drugs Market Perspective (2018-2029)
2.2 Global Microbiome Drugs Growth Trends by Region
2.2.1 Microbiome Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Microbiome Drugs Historic Market Size by Region (2018-2023)
2.2.3 Microbiome Drugs Forecasted Market Size by Region (2024-2029)
2.3 Microbiome Drugs Market Dynamics
2.3.1 Microbiome Drugs Industry Trends
2.3.2 Microbiome Drugs Market Drivers
2.3.3 Microbiome Drugs Market Challenges
2.3.4 Microbiome Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Microbiome Drugs by Players
3.1.1 Global Microbiome Drugs Revenue by Players (2018-2023)
3.1.2 Global Microbiome Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Microbiome Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Microbiome Drugs Market Concentration Ratio
3.4.1 Global Microbiome Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Microbiome Drugs Revenue in 2022
3.5 Global Key Players of Microbiome Drugs Head office and Area Served
3.6 Global Key Players of Microbiome Drugs, Product and Application
3.7 Global Key Players of Microbiome Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Microbiome Drugs Breakdown Data by Type
4.1 Global Microbiome Drugs Historic Market Size by Type (2018-2023)
4.2 Global Microbiome Drugs Forecasted Market Size by Type (2024-2029)
5 Microbiome Drugs Breakdown Data by Symptom
5.1 Global Microbiome Drugs Historic Market Size by Symptom (2018-2023)
5.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2024-2029)
6 North America
6.1 North America Microbiome Drugs Market Size (2018-2029)
6.2 North America Microbiome Drugs Market Size by Type
6.2.1 North America Microbiome Drugs Market Size by Type (2018-2023)
6.2.2 North America Microbiome Drugs Market Size by Type (2024-2029)
6.2.3 North America Microbiome Drugs Market Share by Type (2018-2029)
6.3 North America Microbiome Drugs Market Size by Symptom
6.3.1 North America Microbiome Drugs Market Size by Symptom (2018-2023)
6.3.2 North America Microbiome Drugs Market Size by Symptom (2024-2029)
6.3.3 North America Microbiome Drugs Market Share by Symptom (2018-2029)
6.4 North America Microbiome Drugs Market Size by Country
6.4.1 North America Microbiome Drugs Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Microbiome Drugs Market Size by Country (2018-2023)
6.4.3 North America Microbiome Drugs Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Microbiome Drugs Market Size (2018-2029)
7.2 Europe Microbiome Drugs Market Size by Type
7.2.1 Europe Microbiome Drugs Market Size by Type (2018-2023)
7.2.2 Europe Microbiome Drugs Market Size by Type (2024-2029)
7.2.3 Europe Microbiome Drugs Market Share by Type (2018-2029)
7.3 Europe Microbiome Drugs Market Size by Symptom
7.3.1 Europe Microbiome Drugs Market Size by Symptom (2018-2023)
7.3.2 Europe Microbiome Drugs Market Size by Symptom (2024-2029)
7.3.3 Europe Microbiome Drugs Market Share by Symptom (2018-2029)
7.4 Europe Microbiome Drugs Market Size by Country
7.4.1 Europe Microbiome Drugs Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Microbiome Drugs Market Size by Country (2018-2023)
7.4.3 Europe Microbiome Drugs Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Microbiome Drugs Market Size (2018-2029)
8.2 China Microbiome Drugs Market Size by Type
8.2.1 China Microbiome Drugs Market Size by Type (2018-2023)
8.2.2 China Microbiome Drugs Market Size by Type (2024-2029)
8.2.3 China Microbiome Drugs Market Share by Type (2018-2029)
8.3 China Microbiome Drugs Market Size by Symptom
8.3.1 China Microbiome Drugs Market Size by Symptom (2018-2023)
8.3.2 China Microbiome Drugs Market Size by Symptom (2024-2029)
8.3.3 China Microbiome Drugs Market Share by Symptom (2018-2029)
9 Asia (excluding China)
9.1 Asia Microbiome Drugs Market Size (2018-2029)
9.2 Asia Microbiome Drugs Market Size by Type
9.2.1 Asia Microbiome Drugs Market Size by Type (2018-2023)
9.2.2 Asia Microbiome Drugs Market Size by Type (2024-2029)
9.2.3 Asia Microbiome Drugs Market Share by Type (2018-2029)
9.3 Asia Microbiome Drugs Market Size by Symptom
9.3.1 Asia Microbiome Drugs Market Size by Symptom (2018-2023)
9.3.2 Asia Microbiome Drugs Market Size by Symptom (2024-2029)
9.3.3 Asia Microbiome Drugs Market Share by Symptom (2018-2029)
9.4 Asia Microbiome Drugs Market Size by Region
9.4.1 Asia Microbiome Drugs Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Microbiome Drugs Market Size by Region (2018-2023)
9.4.3 Asia Microbiome Drugs Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Microbiome Drugs Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Microbiome Drugs Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Symptom
10.3.1 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Symptom (2018-2023)
10.3.2 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Symptom (2024-2029)
10.3.3 Middle East, Africa, and Latin America Microbiome Drugs Market Share by Symptom (2018-2029)
10.4 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Microbiome Drugs Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Seres Therapeutics
11.1.1 Seres Therapeutics Company Details
11.1.2 Seres Therapeutics Business Overview
11.1.3 Seres Therapeutics Microbiome Drugs Introduction
11.1.4 Seres Therapeutics Revenue in Microbiome Drugs Business (2018-2023)
11.1.5 Seres Therapeutics Recent Developments
11.2 Assembly Biosciences
11.2.1 Assembly Biosciences Company Details
11.2.2 Assembly Biosciences Business Overview
11.2.3 Assembly Biosciences Microbiome Drugs Introduction
11.2.4 Assembly Biosciences Revenue in Microbiome Drugs Business (2018-2023)
11.2.5 Assembly Biosciences Recent Developments
11.3 Synthetic Biologics
11.3.1 Synthetic Biologics Company Details
11.3.2 Synthetic Biologics Business Overview
11.3.3 Synthetic Biologics Microbiome Drugs Introduction
11.3.4 Synthetic Biologics Revenue in Microbiome Drugs Business (2018-2023)
11.3.5 Synthetic Biologics Recent Developments
11.4 Interxon
11.4.1 Interxon Company Details
11.4.2 Interxon Business Overview
11.4.3 Interxon Microbiome Drugs Introduction
11.4.4 Interxon Revenue in Microbiome Drugs Business (2018-2023)
11.4.5 Interxon Recent Developments
11.5 PureTech
11.5.1 PureTech Company Details
11.5.2 PureTech Business Overview
11.5.3 PureTech Microbiome Drugs Introduction
11.5.4 PureTech Revenue in Microbiome Drugs Business (2018-2023)
11.5.5 PureTech Recent Developments
11.6 Synlogic
11.6.1 Synlogic Company Details
11.6.2 Synlogic Business Overview
11.6.3 Synlogic Microbiome Drugs Introduction
11.6.4 Synlogic Revenue in Microbiome Drugs Business (2018-2023)
11.6.5 Synlogic Recent Developments
11.7 Enterome BioScience
11.7.1 Enterome BioScience Company Details
11.7.2 Enterome BioScience Business Overview
11.7.3 Enterome BioScience Microbiome Drugs Introduction
11.7.4 Enterome BioScience Revenue in Microbiome Drugs Business (2018-2023)
11.7.5 Enterome BioScience Recent Developments
11.8 4D Pharma
11.8.1 4D Pharma Company Details
11.8.2 4D Pharma Business Overview
11.8.3 4D Pharma Microbiome Drugs Introduction
11.8.4 4D Pharma Revenue in Microbiome Drugs Business (2018-2023)
11.8.5 4D Pharma Recent Developments
11.9 Second Genome
11.9.1 Second Genome Company Details
11.9.2 Second Genome Business Overview
11.9.3 Second Genome Microbiome Drugs Introduction
11.9.4 Second Genome Revenue in Microbiome Drugs Business (2018-2023)
11.9.5 Second Genome Recent Developments
11.10 AOBiome
11.10.1 AOBiome Company Details
11.10.2 AOBiome Business Overview
11.10.3 AOBiome Microbiome Drugs Introduction
11.10.4 AOBiome Revenue in Microbiome Drugs Business (2018-2023)
11.10.5 AOBiome Recent Developments
11.11 Rebiotix
11.11.1 Rebiotix Company Details
11.11.2 Rebiotix Business Overview
11.11.3 Rebiotix Microbiome Drugs Introduction
11.11.4 Rebiotix Revenue in Microbiome Drugs Business (2018-2023)
11.11.5 Rebiotix Recent Developments
11.12 Metabiomics
11.12.1 Metabiomics Company Details
11.12.2 Metabiomics Business Overview
11.12.3 Metabiomics Microbiome Drugs Introduction
11.12.4 Metabiomics Revenue in Microbiome Drugs Business (2018-2023)
11.12.5 Metabiomics Recent Developments
11.13 Ritter Pharmaceuticals
11.13.1 Ritter Pharmaceuticals Company Details
11.13.2 Ritter Pharmaceuticals Business Overview
11.13.3 Ritter Pharmaceuticals Microbiome Drugs Introduction
11.13.4 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2018-2023)
11.13.5 Ritter Pharmaceuticals Recent Developments
11.14 Symberix
11.14.1 Symberix Company Details
11.14.2 Symberix Business Overview
11.14.3 Symberix Microbiome Drugs Introduction
11.14.4 Symberix Revenue in Microbiome Drugs Business (2018-2023)
11.14.5 Symberix Recent Developments
11.15 OpenBiome
11.15.1 OpenBiome Company Details
11.15.2 OpenBiome Business Overview
11.15.3 OpenBiome Microbiome Drugs Introduction
11.15.4 OpenBiome Revenue in Microbiome Drugs Business (2018-2023)
11.15.5 OpenBiome Recent Developments
11.16 Azitra
11.16.1 Azitra Company Details
11.16.2 Azitra Business Overview
11.16.3 Azitra Microbiome Drugs Introduction
11.16.4 Azitra Revenue in Microbiome Drugs Business (2018-2023)
11.16.5 Azitra Recent Developments
11.17 Osel
11.17.1 Osel Company Details
11.17.2 Osel Business Overview
11.17.3 Osel Microbiome Drugs Introduction
11.17.4 Osel Revenue in Microbiome Drugs Business (2018-2023)
11.17.5 Osel Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Oral Dosage Form
Table 3. Key Players of Enteric Capsules
Table 4. Global Microbiome Drugs Market Size Growth Rate by Symptom (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Microbiome Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Microbiome Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Microbiome Drugs Market Share by Region (2018-2023)
Table 8. Global Microbiome Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Microbiome Drugs Market Share by Region (2024-2029)
Table 10. Microbiome Drugs Market Trends
Table 11. Microbiome Drugs Market Drivers
Table 12. Microbiome Drugs Market Challenges
Table 13. Microbiome Drugs Market Restraints
Table 14. Global Microbiome Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Microbiome Drugs Revenue Share by Players (2018-2023)
Table 16. Global Top Microbiome Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2022)
Table 17. Global Microbiome Drugs Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Microbiome Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Microbiome Drugs, Headquarters and Area Served
Table 20. Global Key Players of Microbiome Drugs, Product and Application
Table 21. Global Key Players of Microbiome Drugs, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Microbiome Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Microbiome Drugs Revenue Market Share by Type (2018-2023)
Table 25. Global Microbiome Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Microbiome Drugs Revenue Market Share by Type (2024-2029)
Table 27. Global Microbiome Drugs Market Size by Symptom (2018-2023) & (US$ Million)
Table 28. Global Microbiome Drugs Revenue Share by Symptom (2018-2023)
Table 29. Global Microbiome Drugs Forecasted Market Size by Symptom (2024-2029) & (US$ Million)
Table 30. Global Microbiome Drugs Revenue Share by Symptom (2024-2029)
Table 31. North America Microbiome Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Microbiome Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Microbiome Drugs Market Size by Symptom (2018-2023) & (US$ Million)
Table 34. North America Microbiome Drugs Market Size by Symptom (2024-2029) & (US$ Million)
Table 35. North America Microbiome Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Microbiome Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Microbiome Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Microbiome Drugs Market Size by Symptom (2018-2023) & (US$ Million)
Table 41. Europe Microbiome Drugs Market Size by Symptom (2024-2029) & (US$ Million)
Table 42. Europe Microbiome Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Microbiome Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Microbiome Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Microbiome Drugs Market Size by Symptom (2018-2023) & (US$ Million)
Table 48. China Microbiome Drugs Market Size by Symptom (2024-2029) & (US$ Million)
Table 49. Asia Microbiome Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Microbiome Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Microbiome Drugs Market Size by Symptom (2018-2023) & (US$ Million)
Table 52. Asia Microbiome Drugs Market Size by Symptom (2024-2029) & (US$ Million)
Table 53. Asia Microbiome Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Microbiome Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Microbiome Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Microbiome Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Microbiome Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Microbiome Drugs Market Size by Symptom (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Microbiome Drugs Market Size by Symptom (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Microbiome Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 63. Seres Therapeutics Company Details
Table 64. Seres Therapeutics Business Overview
Table 65. Seres Therapeutics Microbiome Drugs Product
Table 66. Seres Therapeutics Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 67. Seres Therapeutics Recent Developments
Table 68. Assembly Biosciences Company Details
Table 69. Assembly Biosciences Business Overview
Table 70. Assembly Biosciences Microbiome Drugs Product
Table 71. Assembly Biosciences Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 72. Assembly Biosciences Recent Developments
Table 73. Synthetic Biologics Company Details
Table 74. Synthetic Biologics Business Overview
Table 75. Synthetic Biologics Microbiome Drugs Product
Table 76. Synthetic Biologics Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 77. Synthetic Biologics Recent Developments
Table 78. Interxon Company Details
Table 79. Interxon Business Overview
Table 80. Interxon Microbiome Drugs Product
Table 81. Interxon Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 82. Interxon Recent Developments
Table 83. PureTech Company Details
Table 84. PureTech Business Overview
Table 85. PureTech Microbiome Drugs Product
Table 86. PureTech Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 87. PureTech Recent Developments
Table 88. Synlogic Company Details
Table 89. Synlogic Business Overview
Table 90. Synlogic Microbiome Drugs Product
Table 91. Synlogic Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 92. Synlogic Recent Developments
Table 93. Enterome BioScience Company Details
Table 94. Enterome BioScience Business Overview
Table 95. Enterome BioScience Microbiome Drugs Product
Table 96. Enterome BioScience Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 97. Enterome BioScience Recent Developments
Table 98. 4D Pharma Company Details
Table 99. 4D Pharma Business Overview
Table 100. 4D Pharma Microbiome Drugs Product
Table 101. 4D Pharma Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 102. 4D Pharma Recent Developments
Table 103. Second Genome Company Details
Table 104. Second Genome Business Overview
Table 105. Second Genome Microbiome Drugs Product
Table 106. Second Genome Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 107. Second Genome Recent Developments
Table 108. AOBiome Company Details
Table 109. AOBiome Business Overview
Table 110. AOBiome Microbiome Drugs Product
Table 111. AOBiome Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 112. AOBiome Recent Developments
Table 113. Rebiotix Company Details
Table 114. Rebiotix Business Overview
Table 115. Rebiotix Microbiome Drugs Product
Table 116. Rebiotix Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 117. Rebiotix Recent Developments
Table 118. Metabiomics Company Details
Table 119. Metabiomics Business Overview
Table 120. Metabiomics Microbiome Drugs Product
Table 121. Metabiomics Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 122. Metabiomics Recent Developments
Table 123. Ritter Pharmaceuticals Company Details
Table 124. Ritter Pharmaceuticals Business Overview
Table 125. Ritter Pharmaceuticals Microbiome Drugs Product
Table 126. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 127. Ritter Pharmaceuticals Recent Developments
Table 128. Symberix Company Details
Table 129. Symberix Business Overview
Table 130. Symberix Microbiome Drugs Product
Table 131. Symberix Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 132. Symberix Recent Developments
Table 133. OpenBiome Company Details
Table 134. OpenBiome Business Overview
Table 135. OpenBiome Microbiome Drugs Product
Table 136. OpenBiome Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 137. OpenBiome Recent Developments
Table 138. Azitra Company Details
Table 139. Azitra Business Overview
Table 140. Azitra Microbiome Drugs Product
Table 141. Azitra Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 142. Azitra Recent Developments
Table 143. Osel Company Details
Table 144. Osel Business Overview
Table 145. Osel Microbiome Drugs Product
Table 146. Osel Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 147. Osel Recent Developments
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Microbiome Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Microbiome Drugs Market Share by Type: 2022 VS 2029
Figure 3. Oral Dosage Form Features
Figure 4. Enteric Capsules Features
Figure 5. Global Microbiome Drugs Market Size Growth Rate by Symptom, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Microbiome Drugs Market Share by Symptom: 2022 VS 2029
Figure 7. Gastrointestinal Disorders Case Studies
Figure 8. Autoimmune Disorders Case Studies
Figure 9. Diabetes Case Studies
Figure 10. Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. Microbiome Drugs Report Years Considered
Figure 13. Global Microbiome Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Microbiome Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Microbiome Drugs Market Share by Region: 2022 VS 2029
Figure 16. Global Microbiome Drugs Market Share by Players in 2022
Figure 17. Global Top Microbiome Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Microbiome Drugs Revenue in 2022
Figure 19. North America Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Microbiome Drugs Market Share by Type (2018-2029)
Figure 21. North America Microbiome Drugs Market Share by Symptom (2018-2029)
Figure 22. North America Microbiome Drugs Market Share by Country (2018-2029)
Figure 23. United States Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Microbiome Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Microbiome Drugs Market Share by Type (2018-2029)
Figure 27. Europe Microbiome Drugs Market Share by Symptom (2018-2029)
Figure 28. Europe Microbiome Drugs Market Share by Country (2018-2029)
Figure 29. Germany Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Microbiome Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Microbiome Drugs Market Share by Type (2018-2029)
Figure 37. China Microbiome Drugs Market Share by Symptom (2018-2029)
Figure 38. Asia Microbiome Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Microbiome Drugs Market Share by Type (2018-2029)
Figure 40. Asia Microbiome Drugs Market Share by Symptom (2018-2029)
Figure 41. Asia Microbiome Drugs Market Share by Region (2018-2029)
Figure 42. Japan Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Microbiome Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Microbiome Drugs Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Microbiome Drugs Market Share by Symptom (2018-2029)
Figure 51. Middle East, Africa, and Latin America Microbiome Drugs Market Share by Country (2018-2029)
Figure 52. Brazil Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Seres Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 59. Assembly Biosciences Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 60. Synthetic Biologics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 61. Interxon Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 62. PureTech Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 63. Synlogic Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 64. Enterome BioScience Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 65. 4D Pharma Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 66. Second Genome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 67. AOBiome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 68. Rebiotix Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 69. Metabiomics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 70. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 71. Symberix Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 72. OpenBiome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 73. Azitra Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 74. Osel Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
|
Global Microbiome Drugs Market Research Report 2023
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from... |
|
Global Microbiome Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028
A microbial drug is a drug made with microorganisms. According to the source, it is divided into three categories: drugs derived from the whole or part of the microorganisms, drugs derived from the primary metabolites of microorganisms, and drugs der... |
|
Global Microbiome Drugs Market Growth (Status and Outlook) 2023-2029
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from... |
|
Global Microbiome Drugs Professional Survey Report 2023, Forecast to 2028
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients c... |
|
Global Microbiome Drugs Market Research Report 2023, Forecast to 2028
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients c... |
|
Global Microbiome Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Market Overview of Global Microbiome Drugs market: According to our latest research, the global Microbiome Drugs market looks promising in the next 5 years. As of 2022, the global Microbiome Drugs market was estimated at USD XX million, and itÂ’... |
|
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029
“Increasing demand for personalized medicine” The human microbiome market is projected to reach USD 1.7 billion by 2029 from USD 0.3 billion in 2023, at a CAGR of 36.1% during the forecast period. The key facto... |
|
Global Human Microbiome Based Drugs and Diagnostics Market Research Report 2023
The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in b... |
|
Global Human Microbiome Based Drugs and Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029
The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in b... |
|
Global Human Microbiome Therapeutic Drugs Market Research Report 2023
Human microbiome therapeutic drugs are drugs made by using the relationship between the gene content of the microbiota and metabolic activities. Highlights The global Human Microbiome Therapeutic Drugs market was valued at US$ million i... |
